These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 18359335)

  • 1. Celecoxib and hypertension-insights from the effect of celecoxib on restenosis after coronary angioplasty with a taxus stent trial.
    Bangalore S; Khianey S; Messerli FH
    Am J Cardiol; 2008 Apr; 101(7):1068. PubMed ID: 18359335
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of celecoxib on restenosis after coronary intervention and evolution of atherosclerosis (Mini-COREA) trial: celecoxib, a double-edged sword for patients with angina.
    Kang HJ; Oh IY; Chung JW; Yang HM; Suh JW; Park KW; Kwon TK; Lee HY; Cho YS; Youn TJ; Koo BK; Kang WY; Kim W; Rha SW; Bae JH; Chae IH; Choi DJ; Kim HS
    Eur Heart J; 2012 Nov; 33(21):2653-61. PubMed ID: 22408034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study.
    Koo BK; Kim YS; Park KW; Yang HM; Kwon DA; Chung JW; Hahn JY; Lee HY; Park JS; Kang HJ; Cho YS; Youn TJ; Chung WY; Chae IH; Choi DJ; Oh BH; Park YB; Kim HS
    Lancet; 2007 Aug; 370(9587):567-74. PubMed ID: 17707751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary artery restenosis: a paradigm of current treatment approaches.
    Kiernan TJ; Kiernan GD; Yan BD
    Minerva Cardioangiol; 2009 Feb; 57(1):77-94. PubMed ID: 19202520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mounting evidence for safety and improved outcomes of drug-eluting stenting: but is it the stent?
    King SB; Hannan EL
    Circulation; 2008 Oct; 118(18):1783-4. PubMed ID: 18852362
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of restenosis in drug-eluting stents: still a challenge!
    Gupta M; Kadakia J; Budoff MJ
    J Invasive Cardiol; 2010 May; 22(5):220-1. PubMed ID: 20440038
    [No Abstract]   [Full Text] [Related]  

  • 8. One-year outcomes with the Taxus Liberté stent in the real world: the Taxus Olympia registry (phase I).
    Ahmed WH; Zambahari R; Al-Rashdan I; Al Naeemi A; Saeed FA; Mascioli S
    J Interv Cardiol; 2008 Dec; 21(6):512-8. PubMed ID: 18973513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late in-stent restenosis in a patient with drug-eluting stent.
    Sultan FA; Kazmi K; Dhakam S; Quraishi AU
    J Coll Physicians Surg Pak; 2005 Oct; 15(10):648-9. PubMed ID: 19810309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying drug-eluting stents in clinical practice.
    King SB
    Am J Cardiol; 2007 Sep; 100(5A):25K-31K. PubMed ID: 17719350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug-eluting stents for diabetic patients. A critical appraisal of the currently available data from randomized trials].
    Silber S; Herdeg C
    Herz; 2008 Apr; 33(3):196-205. PubMed ID: 18568314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bifurcation coronary artery disease: current techniques and future directions (part 2).
    Rizik DG; Klassen KJ; Hermiller JB
    J Invasive Cardiol; 2008 Mar; 20(3):135-41. PubMed ID: 18316830
    [No Abstract]   [Full Text] [Related]  

  • 16. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry).
    Fröbert O; Lagerqvist B; Carlsson J; Lindbäck J; Stenestrand U; James SK
    J Am Coll Cardiol; 2009 May; 53(18):1660-7. PubMed ID: 19406341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating coronary bifurcations: neither rhyme nor reason?
    El-Jack S
    J Interv Cardiol; 2009 Jun; 22(3):257-60. PubMed ID: 19638098
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiology patient page. Drug-eluting stents.
    Maisel WH; Laskey WK
    Circulation; 2007 May; 115(17):e426-7. PubMed ID: 17470700
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug-eluting stents: a comprehensive appraisal.
    Butt M; Connolly D; Lip GY
    Future Cardiol; 2009 Mar; 5(2):141-57. PubMed ID: 19371189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The drug-eluting stent saga.
    Windecker S; Jüni P
    Circulation; 2009 Feb; 119(5):653-6. PubMed ID: 19204314
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.